Dividend Policy Gross Profit Net Profit

As a worldwide science-based biopharmaceutical company AstraZeneca dedicates its resources to upgrading patient healthcare across the globe. AstraZeneca drives clinical progress through prescription drug development while innovating essential therapeutic fields of cancer medicine, cardiovascular treatments, kidney diseases, respiratory problems and immunological disorders and vaccine solutions. The company makes progress through research in rare diseases with the help of modern artificial intelligence technologies to transform healthcare practices (Bekaert & Hodrick, 2014).

AstraZeneca uses its regional business model alongside sustainable innovation practices to speed up scientific discoveries through data analysis and AI and digital technology applications aimed at global healthcare advancement. All business operations at the company operate according to strict governance principles that maintain patient welfare on equal footing with investor interests​

AstraZeneca leads the pharmaceutical industry through continued expansion of its growth and scientific innovation along with its worldwide solutions for complex health challenges. Using a future-oriented strategy the company works to enhance healthcare results by providing transformational drugs to medical patients worldwide.

1.      Section A- Two recent developments & their impact

The worldwide biopharmaceutical company AstraZeneca has made multiple important developments throughout recent months. Two notable ones are:

1-     Expansion and Subsequent Cancellation of the UK Vaccine Plant Project:

AstraZeneca made plans in 2025 to strengthen its vaccine production capabilities by establishing a new pharmaceutical plant in Liverpool worth £450 million. The vaccine production capability of the company would experience increased capacity through this expansion. AstraZeneca terminated its plans for the UK Vaccine Plant development after discovering it was too expensive to proceed even though the British government previously committed £90 million in financial assistance. Because the Labour government reduced its financial backing through spending cuts AstraZeneca decided to stop funding the project. CEO Pascal Soriot acted frustrated about the project cancellation because he saw the challenging investment competition worldwide while confirming that Singapore supported their vaccine production site.

2-     Legal Challenges and Regulatory Investigations in China:

AstraZeneca works through multiple legal and regulatory obstacles in Chinese markets where it operates as its second major market. AstraZeneca became a target in late 2024 after customers in the United States filed a class-action suit alleging fraudulent statements from company leaders Pascal Soriot and Aradhana Sarin together with AstraZeneca about Chinese authority regulatory investigations. AstraZeneca conducts investigations about medical insurance fraud and illegal drug importation and employee data breaches involving their current staff and personnel who previously worked for them. AstraZeneca suffered a 15% drop in market value after Leon Wang became China president during the time of court cases.

3-     ​ Strategy to Address These Challenges:

AstraZeneca has initiated multiple strategic measures for overcoming these difficulties.

• The company increased its stakeholder engagement through honest talks that addressed both legal investigations and project abolition concerns. Pascal Soriot defended the UK vaccine plant expansion termination by demonstrating economic reasons instead of withholding support from the government (Lumby & Jones, 2015).
• AstraZeneca broadened its investment footprint by constructing manufacturing sites and research centers in multiple international markets because the business environment has become increasingly competitive. This approach with substantial support for the Singapore facility protects global operations from major disruptions caused by first region setbacks.
• AstraZeneca conducts increased compliance program development and regulatory authority collaboration for managing legal allegations which face the company. Other details are absent but the company normally puts such measures into effect during legal disputes and regulatory investigations.

Corporate strategies enable AstraZeneca to disrupt external challenges while protecting its stakeholder relationships and sustaining market growth.

2.      Section B- Dividend policy and Source of finance

a-     Dividend policy

The global pharmaceutical company AstraZeneca PLC operates a shareholder-friendly dividend regime which continues to show increasing payments to shareholders. The company increased dividends every year during the last three years as part of its dedication to provide value to shareholders through financial excellence.

1-     Dividend History (2022–2024):

2-     Dividend Policy and Theory:

AstraZeneca follows an advancing dividend strategy which means it increases dividends annually. The business strategy incorporates shareholder benefits while allowing for sustainable business development and financial steadiness. The board uses its earnings outlook for the investment cycle to guide dividend decisions because it ensures sustainable payments which match long-term corporate objectives (Bender, 2014).

3-     Impact of Recent Developments on Dividend Policy:

Developments throughout 2024 have affected how AstraZeneca manages its dividend program.

• In April 2024 AstraZeneca carried out a 2.45% rise in its annual dividend payout which boosted the total payment from $2.90 to $2.97 per share. The company achieved financial success and dedicated itself to shareholder value delivery while raising its annual dividend payment this year.
• The 2024 year brought legal hurdles for AstraZeneca when U.S. class-action representatives sued the firm about Chinese regulatory investigations. The company confirmed its dividend growth while simultaneously proving its confidence in its financial health through this decision.
• During February 2025 AstraZeneca maintained financial performance expectations for both revenue growth of high single-digit percentages and core earnings growth of low double digits while operating under Chinese regulatory hurdles. The optimistic view regarding the future raises optimism about maintaining their dividend policy.

4-     Financial Figures Supporting Dividend Policy:

• AstraZeneca maintains a satisfactory financial position which provides strong support for its dividend policy.
• The dividend yield measured 2.22 percent based on a stock price of $66.87 with annual pay-out of $2.97 per share in February 2025.
• Financial indicators show that AstraZeneca maintains strong financial health alongside its capability for increasing dividends during difficult economic times.

b-     Source of finance

1-      Changes in the Equity and Non-Current Liabilities

The total shareholders’ equity at AstraZeneca rose to $39,166 million in 2023 by growing $1,705 million to value of $40,871 million in the year 2024. The company experienced substantial profit growth that acted as the main cause for its total shareholder equity expansion. Total outstanding debt increased by $91 million. The net amount of cash and cash equivalents reduced to $5,488 million during this period since 2023 when it totalled $5,840 million (Ward, 2014).

Total non-current liabilities experienced minor reduction because the interest-bearing loans and borrowings decreased from $29,232 million in 2022 to $28,622 million in 2023. Traditional debt obligations are decreasing mostly through the bank loan repayment and floating-rate notes payback.

2-      Gearing Ratio Calculation for the Last Two Years

The financial leverage of the company decreased as calculated through the gearing ratio analysis. The 2023 gearing ratio amounted to 57.12% based on the relationship between $39,166 million of net debt and $40,871 million of shareholder equity. The ratio decreased from 57.12% (2023) where net debt amounted to $22,374 million and equity reached $39,166 million to 54.90% in 2024 (net debt equaled $22,465 million and equity reached $40,871 million). AstraZeneca demonstrates financial prudence by decreasing its gearing ratio which shows the company prefers lower debt levels to maintain sufficient equity capital for business investments and growth strategies (Muradoglu et al., 2005).

3-      Capital Structure Policy of the Company in Light of the Gearing Ratio

The company implements a moderate capital structure framework through its limited gearing ratio position. The company maintains respectable financial discipline through equity financing which accounts for 57.12% of its structure in 2023. AstraZeneca continues to lower its debt levels since it chooses to establish a more balanced financial structure between debt and equity. AstraZeneca maintains an investment-grade credit rating that allows them to access financing at attractive prices together with low borrowing expenses. AstraZeneca combines its capital structure with specific operational expenses to fund important acquisitions resembling the 2023 Neogene Therapeutics purchase for $267 million while managing debt to reduce financial risks (Muradoglu et al., 2005).

4-      Financial Risk and Cash Management Issues Concerning AstraZeneca

AstraZeneca encounters various financial security challenges as well as problems with cash management in which:

• The company holds substantial floating-rate debt that makes it susceptible to adjustments in interest rate movements. The company addresses this risk through interest rate swaps yet a substantial increase in interest rates will lead to higher borrowing expenses.
• Due to its worldwide business operations AstraZeneca encounters risks stemming from foreign currency markets. Multi-region operations between AstraZeneca lead to currency exchange rate volatility that affects its earnings particularly in emerging market countries. The pharmaceutical company AstraZeneca protects itself against market uncertainties through hedging approaches.
• The management of cash reserves remains vital for AstraZeneca since the company makes major research and development investments and acquisition deals. The company holds a substantial amount of cash worth $5,840 million throughout its 2023 financial period. To remain solvent AstraZeneca needs to manage cash properly yet maintain enough liquidity to fulfill necessary operating expenses including debt payments and dividend distributions. (Muradoglu et al., 2005)

AstraZeneca maintains sound financial position by using hedging and diversification strategies yet external market elements like interest rate fluctuations as well as exchange rate uncertainties warrant continuous monitoring for stability.

3.      Section C- Ratio Analysis

1-     Net Profit

Profitability measurement depends upon calculating Net Profit Margin as a ratio of net income against total revenue followed by multiplication by 100. The measure shows precisely how much profit exceeds one dollar of revenue after accounting for all expense classifications including taxation and interest costs. Profitability remained constant for AstraZeneca in 2023 and 2024 as the Net Profit Margin stayed at 13.02% throughout both years. AstraZeneca demonstrated effective cost management coupled with operational efficiency since its net income followed the same level of growth as revenue in 2024. AstraZeneca faced no external issues that affected its profitability because its market position remained strong (Budiyanta, 2021).

2-     Gross Profit

The Gross Profit Margin calculation determines business productivity levels by revealing the remaining percentage of sales revenue after deducting Cost of Goods Sold (COGS) expenses. During 2023 AstraZeneca achieved a gross profit margin of 81.9% before this percentage dropped to 81.1% in 2024. Multiple factors including the alterations in product assortment and raw materials and production operations expenses contributed to this 0.8 percentage point decrease. The gross profit experienced an overall improvement but its decreasing trend indicates AstraZeneca encountered minor challenges on production costs not allowing the same level of manufacturing efficiency (Budiyanta, 2021).

3-     Current Ratio

Liquidity analysis through the Current Ratio calculates the relation between current assets against current liabilities in a company. The ratio demonstrates how well the company can use its short-term assets to fulfill its short-term debt obligations. The currently reported ratio indicates declining short-term financial liquidity for AstraZeneca as it decreased from 0.93 during 2023 to 0.85 during 2024. AstraZeneca’s current liability component has grown possibly through increased borrowing or elevated amounts of accounts payable. The current ratio at 0.85 indicates AstraZeneca faces higher pressure on short-term obligations due to its slightly deteriorated liquidity position when compared to last year (Sari et al., 2022).

4-     Quick Ratio (Acid-Test Ratio)

The Quick Ratio (also known as Acid-Test Ratio) represents a robust version of current ratio because it eliminates inventory from the assessment of short-term liquidity by evaluating a company’s ability to pay debts without inventory sales. AstraZeneca’s ability to pay short-term obligations using fast-moving assets decreased during the 2023-2024 period since the Quick Ratio dropped to 0.68 from 0.73. An increase in current liabilities seems to be the reason behind this ratio decrease since the company raised more short-term borrowings along with trade payables. AstraZeneca’s declining Quick Ratio indicates poor short-term liquidity resulting in foreseeable financial challenges for the firm unless it draws from either inventory stocks or outside funding sources (Sari et al., 2022).

5-     Inventory Turnover Ratio

A company determines its Inventory Turnover Ratio through assessment of inventory cycles and restocking frequency during the selected period. Better inventory management efficiency shows up when a company has a higher ratio at a particular time. The metrics available in the financial sector demonstrate that AstraZeneca effectively improved its inventory management performance because its Inventory Turnover Ratio grew from 1.5 in 2023 to 1.9 in 2024. The higher turnover rate for stock demonstrates better inventory performance mainly because of increased demand for medical products including rare disease medications along with oncology offerings from AstraZeneca. The company’s increased speed in product sales improvement creates positive effects on cash flow and working capital (Suraya, 2018).

6-     Accounts Receivable Turnover Ratio

The Accounts Receivable Turnover Ratio shows the level of efficiency in which companies retrieve their unpaid invoices. A company obtains this ratio by dividing its total revenue numbers with its average accounts receivable balance. The Accounts Receivable Turnover Ratio for AstraZeneca increased from 4.29 in 2023 to 5.06 in 2024 because the company improved its customer payment collection efficiency. The rising turnover reflects either improved credit management methods or possibly improved payment conditions AstraZeneca secured from its customers. AstraZeneca succeeded in shortening the cash conversion cycle for its receivables that improved both its liquidity along with cash flow position (Suraya, 2018).

7-     Accounts Receivable to Payable Ratio

The Accounts Receivable to Payable Ratio compares trade receivable volume to trade payable amount to demonstrate short-term financial obligation management performance. The Accounts Receivable to Payable Ratio of AstraZeneca has held steady at 0.37 during both 2023 and 2024 and exhibits that receivership obligations annually represent about 37% of the total payable liabilities. AstraZeneca has successfully kept its Accounts Receivable to Payable Ratio at 0.37 in both 2023 and 2024 which demonstrates that the company maintains balanced working capital management. The company depends on its working capital to achieve efficient receivable and payable gaps matching (Suraya, 2018).

8-     Earnings per Share (EPS)

The fundamental profitability indicator Earnings per Share (EPS) calculates the specific amount companies distribute per outstanding share of common stock. The earnings per share (EPS) of AstraZeneca went up from $3.84 in 2023 to $4.54 in 2024 thus indicating robust profit growth. The company increased EPS numbers which shows it generated additional shareholder value by achieving higher financial performance even during times of rising expenses and market competition. Better EPS serves as evidence that AstraZeneca maintains sound financial wellness and demonstrates strong capabilities to provide stockholder wealth (Farah Freihat, 2019).

9-     Price to Earnings (P/E) Ratio

The Price to Earnings ratio examines business stock value versus earnings per share to determine stock purchase decisions by evaluating market value versus earnings performance. The P/E Ratio of AstraZeneca decreased from 31.5 in 2023 to 26.6 in 2024 which indicates the market adjusted its estimated growth rate of the company. The declining stock price suggests investors find the company’s valuation in relation to earnings more suitable for investment purposes. An undervalued stock shows indicators through a low P/E ratio if the company maintains positive performance (Ou & Penman, 1989).

4.      Conclusion: Overall Financial Performance Evaluation

The specific ratios present distinctive perspectives about different operational aspects and financial stability of AstraZeneca. Changes in two performance indicators demonstrate positive trends but short-term liquidity challenges appear through unsatisfactory changes in the Current Ratio and Quick Ratio. The company’s business expansion shows effective management mainly through strong profit margins and efficient day-to-day operations.

5. Reference

• Bekaert, G. and Hodrick, R.J. (2014) International Financial Management. Harlow, Essex, England: Pearson Education Limited.
• Bender, R. (2014) Corporate financial strategy. London: Routledge/Taylor & Francis Group.
• Budiyanta, W.A. (2021) ‘A  literature review of net profit margin’, Social Science Studies, 1(2), pp. 115–128. doi:10.47153/sss12.2262021.
• Farah Freihat, A.R. (2019) ‘Factors affecting price to earnings ratio (P/E): Evidence from the emerging market’, Risk Governance and Control: Financial Markets and Institutions, 9(2), pp. 47–56. doi:10.22495/rgcv9i2p4.
• Lumby, S. and Jones, C.M. (2015) Corporate finance: Theory and practice. Andover: Cengage Learning.
• Muradoglu, G., Bakke, M. and Kvernes, G.L. (2005) ‘An investment strategy based on gearing ratio’, Applied Economics Letters, 12(13), pp. 801–804. doi:10.1080/13504850500365780.
• Ou, J.A. and Penman, S.H. (1989) ‘Accounting measurement, price-earnings ratio, and the information content of security prices’, Journal of Accounting Research, 27, p. 111. doi:10.2307/2491068.
• Sari, W.N. et al. (2022) ‘Effect of current ratio (CR), Quick Ratio (QR), debt to asset ratio (DAR) and debt to equity ratio (DER) on return on assets (ROA)’, Journal of Islamic Economics and Business, 2(1), pp. 42–58. doi:10.15575/jieb.v2i1.20173.
• Suraya, A. (2018) ‘The influence of accounts receivable turnover and inventory turnover on profitability at PT Sumber Alfaria trijaya tbk’, PINISI Discretion Review, 2(1), p. 77. doi:10.26858/pdr.v2i1.13246.
• Ward, A.M. (2014) Finance: Theory and practice. Dublin, Ireland: Chartered Accountants Ireland.